(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures front patients with Paget's disease

Seiichi Ishizuka, Noriyoshi Kurihara, Sakamuri V. Reddy, Julian Cornish, Tim Gundy, G. David Roodman

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Osteoclast (OCL) precursors from patients with Paget's disease (PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene (MVNP) are hyperresponsive to 1α,25-dihydroxyvitamin D3 [1α,25-(OH)2D3] and can form OCLs at physiologic concentrations of 1α,25-(OH)2D3. This hyperresponsivity to 1α,25-(OH)2D3 is due to increased expression of TATA box-associated factor II-17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1α,25-(OH) 2D3 may permit OCL formation in PD patients with low levels of 1α,25-(OH)2D3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI-9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10 -6 M. However, it dose-dependently (10-10 M to 10 -6 M) inhibited osteoclast formation induced by concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) detected in PD patients by bone marrow cells of patients with PD and MVNP-transduced colony-forming unit-granulocyte macrophage (CFU-GM) cells, which form pagetic-like OCL. Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10-9 M 1α,25-(OH) 2D3 was dose-dependently inhibited by TEI-9647 (10 -9 M to 10-6 M). Furthermore, 10-7 M TEI-9647 by itself did not cause 1α,25-(OH)2D3-dependent gene expression but almost completely suppressed expression of the TATA box-associated factor II-17 and 25-hydroxyvitamin D3-24-hydroxylase genes induced by 1α,25-(OH)2D3 treatment of MVNP-transduced CFU-GM cells. These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD.

Original languageEnglish (US)
Pages (from-to)2023-2030
Number of pages8
JournalEndocrinology
Volume146
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Calcitriol Receptors
Osteoclasts
Bone Resorption
Bone Marrow
Granulocyte-Macrophage Progenitor Cells
TATA-Binding Protein Associated Factors
TATA Box
Genes
Osteitis Deformans
Calcifediol
TEI 9647
Calcitriol
Mixed Function Oxygenases
Vitamin D
Bone Marrow Cells
Gene Expression
measles virus nucleocapsid protein

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{986081a106664aae94d60bac6ddab232,
title = "(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures front patients with Paget's disease",
abstract = "Osteoclast (OCL) precursors from patients with Paget's disease (PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene (MVNP) are hyperresponsive to 1α,25-dihydroxyvitamin D3 [1α,25-(OH)2D3] and can form OCLs at physiologic concentrations of 1α,25-(OH)2D3. This hyperresponsivity to 1α,25-(OH)2D3 is due to increased expression of TATA box-associated factor II-17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1α,25-(OH) 2D3 may permit OCL formation in PD patients with low levels of 1α,25-(OH)2D3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI-9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10 -6 M. However, it dose-dependently (10-10 M to 10 -6 M) inhibited osteoclast formation induced by concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) detected in PD patients by bone marrow cells of patients with PD and MVNP-transduced colony-forming unit-granulocyte macrophage (CFU-GM) cells, which form pagetic-like OCL. Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10-9 M 1α,25-(OH) 2D3 was dose-dependently inhibited by TEI-9647 (10 -9 M to 10-6 M). Furthermore, 10-7 M TEI-9647 by itself did not cause 1α,25-(OH)2D3-dependent gene expression but almost completely suppressed expression of the TATA box-associated factor II-17 and 25-hydroxyvitamin D3-24-hydroxylase genes induced by 1α,25-(OH)2D3 treatment of MVNP-transduced CFU-GM cells. These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD.",
author = "Seiichi Ishizuka and Noriyoshi Kurihara and Reddy, {Sakamuri V.} and Julian Cornish and Tim Gundy and Roodman, {G. David}",
year = "2005",
month = "4",
doi = "10.1210/en.2004-1140",
language = "English (US)",
volume = "146",
pages = "2023--2030",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures front patients with Paget's disease

AU - Ishizuka, Seiichi

AU - Kurihara, Noriyoshi

AU - Reddy, Sakamuri V.

AU - Cornish, Julian

AU - Gundy, Tim

AU - Roodman, G. David

PY - 2005/4

Y1 - 2005/4

N2 - Osteoclast (OCL) precursors from patients with Paget's disease (PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene (MVNP) are hyperresponsive to 1α,25-dihydroxyvitamin D3 [1α,25-(OH)2D3] and can form OCLs at physiologic concentrations of 1α,25-(OH)2D3. This hyperresponsivity to 1α,25-(OH)2D3 is due to increased expression of TATA box-associated factor II-17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1α,25-(OH) 2D3 may permit OCL formation in PD patients with low levels of 1α,25-(OH)2D3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI-9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10 -6 M. However, it dose-dependently (10-10 M to 10 -6 M) inhibited osteoclast formation induced by concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) detected in PD patients by bone marrow cells of patients with PD and MVNP-transduced colony-forming unit-granulocyte macrophage (CFU-GM) cells, which form pagetic-like OCL. Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10-9 M 1α,25-(OH) 2D3 was dose-dependently inhibited by TEI-9647 (10 -9 M to 10-6 M). Furthermore, 10-7 M TEI-9647 by itself did not cause 1α,25-(OH)2D3-dependent gene expression but almost completely suppressed expression of the TATA box-associated factor II-17 and 25-hydroxyvitamin D3-24-hydroxylase genes induced by 1α,25-(OH)2D3 treatment of MVNP-transduced CFU-GM cells. These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD.

AB - Osteoclast (OCL) precursors from patients with Paget's disease (PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene (MVNP) are hyperresponsive to 1α,25-dihydroxyvitamin D3 [1α,25-(OH)2D3] and can form OCLs at physiologic concentrations of 1α,25-(OH)2D3. This hyperresponsivity to 1α,25-(OH)2D3 is due to increased expression of TATA box-associated factor II-17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1α,25-(OH) 2D3 may permit OCL formation in PD patients with low levels of 1α,25-(OH)2D3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI-9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10 -6 M. However, it dose-dependently (10-10 M to 10 -6 M) inhibited osteoclast formation induced by concentrations of 1α,25-(OH)2D3 (41 pg/ml, 10-10 M) detected in PD patients by bone marrow cells of patients with PD and MVNP-transduced colony-forming unit-granulocyte macrophage (CFU-GM) cells, which form pagetic-like OCL. Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10-9 M 1α,25-(OH) 2D3 was dose-dependently inhibited by TEI-9647 (10 -9 M to 10-6 M). Furthermore, 10-7 M TEI-9647 by itself did not cause 1α,25-(OH)2D3-dependent gene expression but almost completely suppressed expression of the TATA box-associated factor II-17 and 25-hydroxyvitamin D3-24-hydroxylase genes induced by 1α,25-(OH)2D3 treatment of MVNP-transduced CFU-GM cells. These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD.

UR - http://www.scopus.com/inward/record.url?scp=15444372148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444372148&partnerID=8YFLogxK

U2 - 10.1210/en.2004-1140

DO - 10.1210/en.2004-1140

M3 - Article

C2 - 15618361

AN - SCOPUS:15444372148

VL - 146

SP - 2023

EP - 2030

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 4

ER -